Tachykinin non-peptide antagonists: binding domain and molecular mode of action.
Gether
U
U
Howard Hughes Medical Institute, Beckman Center, Stanford University Medical Center, CA 94305, USA.
Lowe
J A
JA
Schwartz
T W
TW
D000818:Animals; D001549:Benzamides / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive; D001713:Biphenyl Compounds / Q000378:metabolism / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D015288:Neurokinin A / Q000378:metabolism / Q000494:pharmacology; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology; D017354:Point Mutation; D017433:Protein Structure, Secondary; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011993:Recombinant Fusion Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry; D013373:Substance P / Q000378:metabolism / Q000494:pharmacology; D015320:Tachykinins / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism
D001549:Benzamides; D001713:Biphenyl Compounds; D010880:Piperidines; D018039:Receptors, Tachykinin; D011993:Recombinant Fusion Proteins; D015320:Tachykinins; D013373:Substance P; C073839:SR 48968; D015288:Neurokinin A; D019204:GTP-Binding Proteins; C066892:CP 96345